Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
IGFBP7 Double Nickase Plasmid (h): sc-418272-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IGFBP7 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- IGFBP7 Double Nickase Plasmid (h) and IGFBP7 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting IGFBP7. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: IGFBP7 Antibody (H-3): sc-365293
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IGFBP7 Double Nickase Plasmid (h) | sc-418272-NIC | 20 µg | $410.00 | |||
IGFBP7 Double Nickase Plasmid (h2) | sc-418272-NIC-2 | 20 µg | $410.00 |
IGFBP7 (insulin-like growth factor binding protein 7) is a secreted glycoprotein that modulates IGF/insulin signaling by regulating ligand availability and receptor engagement, influencing cell growth, adhesion, and senescence-associated programs. It contributes to extracellular matrix interactions and stress-responsive signaling, intersecting with pathways that shape endothelial biology, tissue remodeling, and inflammatory microenvironments. Altered IGFBP7 expression has been reported across contexts of fibrosis, vascular dysfunction, and cancer-associated stromal remodeling, where it can affect proliferation and cell–matrix dynamics. As a result, IGFBP7 is frequently studied as a node linking growth factor signaling to extracellular regulation and cellular state transitions.
IGFBP7 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the IGFBP7 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within IGFBP7. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt IGFBP7 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of IGFBP7-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.